Nancy Chen, MD
Ophthalmology · Kapolei, HINPI 1265427900
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,296 of the $6,221 with a category attached, or 85.1%. 26 manufacturers reported payments, led by Alcon at 29.4% of the total.
Across 140 payments — averaging $44.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Amgen$659
- Bausch & Lomb, A Division Of Bausch Health US, LLC$546
- Glaukos Corporation$451
- NEW World Medical,inc.$438
- Johnson & Johnson Surgical Vision, Inc.$408
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,29685%
- Education$701%
- Gifts$170%
- Other$83813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 34 | $1,828 |
| Amgen(2 entities) | 15 | $659 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $546 |
| Glaukos Corporation | 9 | $451 |
| NEW World Medical,inc. | 1 | $438 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $408 |
| Sight Sciences, Inc. | 8 | $303 |
| Aerie Pharmaceuticals, Inc. | 10 | $209 |
| Mallinckrodt Enterprises LLC | 6 | $185 |
| Merz North America, Inc. | 3 | $161 |
| Sun Pharmaceutical Industries Inc. | 6 | $144 |
| Kedrion Biopharma, Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $124 |
| Dompe US, Inc. | 1 | $120 |
| AbbVie | 3 | $86 |
| Bausch & Lomb Americas Inc. | 4 | $83 |
| Novartis | 4 | $70 |
| Kala Pharmaceuticals, Inc. | 3 | $56 |
| Tarsus Pharmaceuticals, Inc. | 2 | $53 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Galderma Laboratories, L.p. | 1 | $27 |
| Harrow Eye, LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Unity$983
- iDoseTR$304
- STELLARIS$208
- iStent Infinite$181
- OMNI(R) SURGICAL SYSTEM (US)$148
- ARGOS$146
- Tecnis Multifocal Family of 1-piece IOLS$125
- TEPEZZA$125
- Coagadex$125
- Lucentis$124
- Oxervate$120
- Clareon$111
- ACTHAR$109
- Catalys Laser System$103
How this compares
$6,221 in reported general payments places this provider in the 70th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 72 | $36,796 |
| Bromfenac Sodium | 109 | $32,399 |
| VyzultaLatanoprostene Bunod | 34 | $18,719 |
| RestasisCyclosporine | 18 | $18,037 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $16,407 |
| ZirganGanciclovir | 30 | $15,217 |
| Brimonidine Tartrate | 43 | $6,999 |
| Latanoprost | 338 | $6,058 |
| Lotemax SmLoteprednol Etabonate | 11 | $3,837 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 166 | $2,338 |
| Prednisolone Acetate | 33 | $2,273 |
| ValacyclovirValacyclovir Hcl | 15 | $923 |
| Timolol Maleate | 98 | $795 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 63 | $751 |
| ErythromycinErythromycin Base | 26 | $514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $546 | $40,63283 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Zirgan | $83 | $33,93564 claims |
| AbbVieRestasis | $86 | $18,03718 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $209 | $16,40722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Kapolei
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Gregg KokameAiea$73K
- Rupa WongHonolulu$72K
- William WongAiea$40K
- Luis OmphroyAiea$25K
- Sarah ReadAiea$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.